Business/Financial Results (Form 8-K)

AbbVie Inc.

Guidance Including the Impact of Acquired IPR&D and Milestones Expense

(Unaudited)

(in millions, except per share data)			Quarter Ended March 31, 2025																		Full-Year Ended December 31, 2025
			Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range												Acquired IPR&D and Milestones Expense						Adjusted Diluted EPS Range
									Low						High												Low						High
Previously announced guidance excluding Q1 2025 acquired IPR&D and milestones expense			$	-					$	2.47					$	2.51					$	-					$	12.12					$	12.32
Q1 2025 acquired IPR&D and milestones expense			248						(0.13)						(0.13)						248						(0.13)						(0.13)
Guidance including Q1 2025 acquired IPR&D and milestones expensea			$	248					$	2.34					$	2.38					$	248					$	11.99					$	12.19

a The Company's 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones expense that may be incurred beyond the first quarter of 2025, as both cannot be reliably forecasted. This guidance does not reflect the impact related to AbbVie and Gubra's licensing agreement to develop GUB014295, as that transaction closed after the first quarter of 2025.

1